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Resumo 
 
A terapia génica envolve a transferência de material genético terapêutico para 
células alvo, pela introdução de genes funcionais que substituam ou complementem 
aqueles que se encontram defeituosos, com o objectivo de tratar ou prevenir uma ampla 
gama de doenças, hereditárias ou adquiridas. No entanto, para o seu sucesso é 
necessário um sistema de entrega de material genético eficiente, capaz de proteger o 
DNA da degradação por nucleases e com o mínimo de toxicidade e imunogeneicidade 
que permita uma expressão genética estável e duradoura. Durante os últimos anos, têm 
sido desenvolvidos uma ampla gama de vectores, que têm sido divididos e 
caracterizados como vectores virais e não virais. Os vectores virais apresentam maior 
eficiência na transferência de material genético, tanto in vitro como in vivo, no entanto 
apresentam algumas limitações como a reduzida capacidade de empacotamento 
genético e o facto de conduzirem a respostas inflamatórias/imunológicas indesejáveis 
que consequentemente limitam administrações subsequentes. Por sua vez, os vectores 
não virais apresentam algumas vantagens sobre os vectores virais, nomeadamente, um 
perfil imunológico mais seguro, uma produção mais fácil, uma maior capacidade de 
empacotamento genético e a sua reduzida toxicidade. Contudo, o uso de vectores não 
virais é limitado devido às suas eficiências de transfecção relativamente baixas, 
marcadas pela baixa translocação nuclear, e consequentemente reduzida expressão 
genética. Vários esforços têm sido realizados no sentido de ultrapassar a barreira 
nuclear, um dos maiores passos limitantes no desenvolvimento de sistemas de entrega 
genética não virais eficazes. Uma das estratégias passa pela incorporação de sinais de 
localização nuclear em complexos poliméricos, uma vez que estes péptidos catiónicos 
ao serem reconhecidos pelas importinas permitem um transporte genético eficaz para o 
núcleo através dos complexos de poros nucleares, aumentando assim a entrega nuclear 
do DNA, e por consequente, a sua expressão genética. 
Neste contexto, o objectivo deste trabalho foi a caracterização e optimização de 
vectores não virais, baseados em polímeros como o quitosano e o ácido hialurónico, que 
foram escolhidos devido às suas notórias propriedades de biocompatibilidade, 
biodegradação e ausência de toxicidade. Péptidos baseados em sinais de localização 
nuclear endógenos, pertencentes á família dos IGFBP, derivados nomeadamente do 
IGFBP-3 e IGFBP-5, foram avaliados com o intuito de melhorar a translocação nuclear 
sem comprometer o perfil imunológico bastante baixo dos vectores não-virais. Várias 
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estratégias foram testadas para avaliar a eficiência de transfecção e a expressão genética 
mediada por poliplexos de quitosano e ácido hialurónico em células HEK293T: 
nomeadamente a co-administração, a co-complexação e a ligação covalente dos 
péptidos IGFBP aos poliplexos de quitosano. 
Os nossos resultados mostraram que as nossas formulações, com ou sem sulfato 
de sódio, péptidos IGFBP ou ácido hialurónico, e independentemente da estratégia 
usada, originaram poliplexos com um intervalo de tamanhos entre 250 nm e 750 nm e 
carga de superfície positiva, caracterizados através de medições no Zetasizer. Os nossos 
poliplexos foram ainda capazes de complexar o DNA de forma eficaz, conforme 
analisado através de ensaios de electroforese em gel de agarose. 
Posteriormente à caracterização dos poliplexos, os péptidos IGFBP foram ainda 
avaliados quanto á sua citotoxicidade em dois períodos de incubação, 24 horas e 72 
horas. Os ensaios de viabilidade celular não mostraram qualquer citotoxicidade para 
ambos os péptidos IGFBP para as várias concentrações testadas nos dois períodos de 
tempo testados. 
Após estes resultados, e uma vez que os poliplexos apresentaram características 
desejáveis quanto ao seu tamanho, carga de superfície e complexação eficiente do DNA, 
estes foram avaliados quanto à sua eficácia através de ensaios de transfecção in vitro, 
analisados posteriormente por microscopia de fluorescência e citometria de fluxo. 
A eficiência de transfecção revelou-se ser dependente da concentração dos 
péptidos IGFBP e variar consoante o método de entrega utilizado. Nos ensaios de 
transfecção, utilizando o método de co-administração dos poliplexos com os péptidos 
IGFBP, nenhum aumento na eficiência de transfecção foi observado. Nos métodos em 
que estratégias como a co-complexação e a ligação covalente dos péptidos IGFBP aos 
poliplexos de quitosano foram usadas, um aumento significativo da eficiência de 
transfecção foi conseguido, no entanto, apenas para os poliplexos associados ao IGFBP-
3. Uma possível explicação para estes resultados é o facto de as acessibilidades e/ou 
afinidades para com as subunidades das importinas diferirem entre os péptidos IGFBP-3 
e IGFBP-5, o que consequentemente, poderá levar a níveis de translocação diferentes 
entre os péptidos, no entanto, ainda não é claro qual o mecanismo. 
Foi ainda possível verificar que combinando polímeros como o quitosano e o 
ácido hialurónico, que os poliplexos resultantes renderam um aumento significativo da 
eficiência de transfecção para ambos os péptidos, IGFBP-3 e IGFBP-5, o que poderá ser 
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explicado por uma possível modificação no enrolamento das cadeias do quitosano 
aquando da adição do ácido hialurónico. 
Na sua globalidade os resultados obtidos demonstraram que, apesar de ser ainda 
necessário uma optimização da eficiência de transfecção, poliplexos co-complexados 
com péptidos IGFBP são de facto bons candidatos a sistemas de entrega genética não 
virais. Os poliplexos com dois polímeros combinados, quitosano e ácido hialurónico, 
foram os que revelaram maiores eficiências de transfecção, para ambos os péptidos, 
IGFBP-3 e IGFBP-5. Futuramente, seria interessante não só expandir a gama de 
concentrações de péptidos IGFBP testadas como também o tipo de linhas celulares, 
compreendendo ainda uma optimização das formulações dos poliplexos. 
 
 
Palavras-Chave: terapia génica, quitosano, ácido hialurónico, sinais de localização 
nuclear, IGFBP-3, IGFBP-5 
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Abstract 
 
Gene therapy entails the transfer of therapeutic genetic material into specific cells; 
however, their success requires an efficient gene delivery system, which allows a stable 
gene expression. Nuclear import is considered the major limiting step in the 
development of effective non-viral gene delivery systems; the incorporation of NLS that 
can mediate nuclear intake can be used as a strategy in order to enhance the 
internalization of DNA into the nucleus. 
In this work, an endogenous NLS peptide, based on IGFBP, namely IGFBP-3 and 
IGFBP-5, was evaluated in order to ameliorate nuclear translocation without 
compromising the fairly low immunological profile of non-viral vectors. Several 
strategies were tested to determine their effect in chitosan and acid hyaluronic polyplex-
mediated transfection efficiency in HEK293T cells: co-administration, co-
complexation, and covalent ligation to chitosan polyplexes. 
Our results show that our vectors are capable of an effective DNA complexation 
and present size and surface charge appropriated for gene delivery applications. 
Transfection efficiency is concentration dependent and varies with the delivery 
method employed. Co-complexation and covalent ligation of IGFBP peptides to 
chitosan polyplexes yielded a 2-fold increase in transfection efficiency associated with 
the use of IGFBP-3 peptides. The incorporation of acid hyaluronic yielded a significant 
increase in transfection efficiency to both peptides. 
Despite of the improvements in transfection efficiency it needs to be further 
improved, these results indicate that polyplexes co-complexed with IGFBP peptides are 
good candidates for non-viral gene delivery systems and would be interesting to expand 
the range of tested IGFBP peptides concentrations as well as the type of cell lines used. 
 
 
Keywords: gene therapy, chitosan, acid hyaluronic, nuclear localization signals, 
IGFBP-3, IGFBP-5 
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1. Introduction 
2 
 
1.1 Gene therapy 
 
Gene therapy entails the transfer of therapeutic genetic material into specific cells 
(tissue or organ) of a patient where production of the encoded protein will occur, in 
order to treat or prevent a disease, altering an existing abnormality by replacement of a 
missing or defective gene, which influence the disease process (Corsi et al., 2003; 
Gorecki, 2006; Nayerossadat et al., 2012; Tiera et al., 2006; Yue et al., 2013). Gene 
therapy has been a promising strategy for the treatment of many genetic and acquired 
diseases, such as cancer (Bremner et al., 2004), heart failure (Doh, 2015), cystic 
fibrosis, emphysema, retinitis pigmentosa, vascular diseases, neurodegenerative 
disorders, inflammatory conditions, acquired immunodeficiency syndrome (AIDS) 
(Cevher et al., 2012; Nayerossadat et al., 2012), among others. Therefore, their success 
requires a gene delivery system of minimal toxicity, capable of protecting 
deoxyribonucleic acid (DNA) from nuclease enzymes until it reaches its target, allowing 
prolonged and stable gene expression (Machado et al., 2014; Tiera et al., 2006). 
Naked DNA is often not sufficient for efficient gene transfer because it is rapidly 
degraded and their cellular intake is fairly low (Corsi et al., 2003; Opanasopit et al., 
2009), due to their hydrophilic arrangement and large size resulting from negatively 
charged phosphates groups (Cevher et al., 2012). For this reason, it is necessary the help 
of a delivery system, referred to as vector, which tends to protect and compact the DNA 
(Dufes et al., 2005). Innumerous efforts have been made to develop a safe and effective 
gene delivery method that minimizes side effects and overcomes the major drawback of 
gene therapy: the low gene transfection rate (Tiera et al., 2006). Thus, the two main 
types of vectors used in gene therapy are based on viral and non-viral gene delivery 
systems (Fig. 1.1). 
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1.2 Delivery vectors 
 
1.2.1 Viral vectors 
 
One of the most successful gene therapy vectors today are viruses-based gene 
delivery systems which provide high transduction effectiveness of the gene of interest to 
the target cells and superior levels of gene expression. Viruses, such as retrovirus, 
lentivirus, adenovirus, among others, can be readily transformed into viral vectors by 
replacing part of their genome in order to use the same space for the therapeutic gene 
(Yue et al., 2013). However, although viral vectors are efficient and removing part of 
their genome reduces their pathogenicity, their capsid can initiate a severe 
immune/inflammatory response. The use of these vectors could be limited due to their 
toxicity and oncogenicity, which limits the possibility of subsequent administrations, 
and moreover, have a reduced capacity to carry a large amount of genetic information 
and lack of optimization in large-scale production (Cevher et al., 2012; Machado et al., 
2014). Viral vectors are distinguished by type of virus used, as depicted in Fig 1.2. 
 
 
 
 
Vector type
Viral vectors
Retroviral
Adenoviral
Adeno-associated viruses
Herpes simplex viruses
Lentiviruses
Non-viral vectors
Physical
Gene gun
Electroporation
Magnetofection
Ultrasound
Chemical
Lipid-based systems
Polymer-based systems
Figure 1.1 - Types of vectors: viral and non-viral vectors (adapted from (Nayerossadat et al., 2012). 
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1.2.2 Non-viral vectors 
 
Over the past years, the limitations of viral vectors, particularly regarding safety 
concerns, have led to the development of alternative gene delivery systems as non-viral 
vectors (Tiera et al., 2006). These vectors have many advantages, such as their safety 
profile, ease of production, greater structural and chemical versatility for manipulation 
of their properties, possibility of repeated administration, cell/tissue targeting and low 
immune responses; however, the biggest drawback of non-viral vectors is their low 
transfection efficiency (Cevher et al., 2012; De Laporte et al., 2006; Ishii et al., 2001; 
Tiera et al., 2006; Wong et al., 2007). The development of effective non-viral vectors 
has been a challenge in the field of gene therapy, and these can be divided in two 
categories, physical and chemical (Fig. 1.1). Physical methods, including gene gun, 
electroporation, magnetofection and ultrasound, are based on the application of a force 
to increase the permeability of the cellular membrane, allowing the gene to enter the cell 
and thus augment gene delivery. While chemical methods, including cationic lipids and 
Viral Vectors
Adeno viruses 
vectors
dsDNA
Up to 38 kb
Dividing and non-
dividing cells
High effectiveness 
in transduction
Short-term gene 
expression, 
immune/inflammat
ory responses
Adeno-associated 
viruses vectors
ssDNA
Up to 4.8 kb
Dividing and non-
dividing cells
Non-pathogenic
Limited transgene 
capacity
Retroviruses 
vectors
RNA
Up to 8 kb
Dividing cells
Low efficiency in 
vivo
Immunogenic 
problems, risk of 
insertion with 
oncogenic 
activation
Lentiviruses 
vectors
RNA
Up to 8 kb
Dividing and non-
diving cells
Neuronotropics 
features, low 
immunogenicity, 
long-term 
expression
Risk of insertion 
mutagenesis
Herpes simplex 
viruses vectors
dsDNA
Up to 150 kb
Dividing and non-
dividing cells
Neuronotropics 
features, large 
transgene capacity 
Short-term 
expression
Figure 1.2 - Examples of viral vectors and their properties, such as type of viruses, viral genome, 
packaging capacity, type of cells transduced, vantages and disadvantages of their use (Cevher et al., 2012; 
Nayerossadat et al., 2012). dsDNA – double stranded DNA, ssDNA – single stranded DNA. 
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polymers, are based on the transport of therapeutic genes across the cell membrane up 
to the nuclear membrane (Cevher et al., 2012; De Laporte et al., 2006). 
1.2.2.1 Physical methods 
 
 Gene Gun 
Gene gun is based on small, spherical DNA-coated heavy metal particles, 
including gold, tungsten and silver particles, which are accelerated to high speed by 
pressurized inert gas to enter into target cells/tissue, such as skin, mucosa or surgically 
exposed tissues. This method presents some advantages such as high reproducibility 
without the use of toxic chemicals or receptors, ability to carry DNA fragments of 
several sizes and the production of metal particles is relatively easy. However, it might 
cause tissue damage and their gene expression is low and short-termed (Cevher et al., 
2012; Nayerossadat et al., 2012). 
 
 Electroporation 
Electroporation is based on controlled temporary destabilization of the cell 
membrane by insertion of a pair of electrodes into it, that produce electric pulses to 
increase cell permeability and to form temporary pores on the membrane surface which 
allows the entry of DNA into the cell. This method has been used in vivo for several 
tissues such as skin, muscle, lung, and tumor treatment, however, irreversible tissue 
damage might occur due to high temperature resulting from the high voltage application 
(Cevher et al., 2012; Nayerossadat et al., 2012). 
 
 Magnetofection 
Magnetofection is based on concentration of particles containing nucleic acid into 
the target cells by the use of magnetic field to increase gene transfer. This method has 
been tested on a wide range of cell types and presents high transfection efficiency and 
low toxicity (Nayerossadat et al., 2012). 
 
 Ultrasound 
Ultrasound is based on the use of acoustic cavitation, which can make some 
nanomeric pores in cell membranes and facilitate intracellular delivery of DNA particles 
1. Introduction 
6 
 
into cells of internal organs or tumors. This method is considered a relatively easy and 
reliable procedure, however their transfection efficiency is low (Newman et al., 2007). 
 
1.2.2.2 Chemical methods 
 
Non-viral gene delivery is constituted mainly by chemical methods of gene 
transfer, such as cationic lipids and polymers that usually form nanomeric complexes by 
electrostatic interactions between negatively charged nucleic acids and positively 
charged lipids or polymers, resulting in lipoplexes or polyplexes, respectively. These 
cationic gene delivery systems, when compared with other non-viral systems, have 
several advantages such as low toxicity and antigenicity, long-term expression with less 
risk of insertional oncogenesis and less tissue damage, among others. However, the 
major drawback is their low transfection efficiency, which can be due to 1) nonspecific 
interactions between cationic complexes and cell surface, 2) the process of endocytosis 
into endocytic vesicles, 3) compaction and release of the DNA from endosomes, which 
differs fundamentally for lipoplexes and polyplexes, and lastly 4) translocation of DNA 
to the nucleus and their expression (Cevher et al., 2012; Nayerossadat et al., 2012). 
 
 Lipid-based systems 
 
Lipid-based gene delivery systems can be divided according to their charges into 
cationic, anionic and neutral, and the most used are lipoplexes, complexes formed by a 
multilayered structure consisting of plasmid sandwiched between cationic lipids. 
Cationic lipids have tree basic constituents: the polar head group, an interconnecting 
linker and a hydrophobic anchor (Fig. 1.3). The hydrophilic head groups are, generally, 
primary, secondary, tertiary amines or quaternary amine salts, which promote 
interactions with DNA, through the negatively charged phosphates groups of DNA with 
the cationic groups present in hydrophilic head, and are largely responsible for its 
toxicity. Linker groups such as amides, esters and ethers, ensure a contact between the 
cationic head group and the negatively charged phosphates of the DNA and define the 
local for lipid cleavage, which affects biodegradability rate. Hydrophobic anchor 
represents the nonpolar hydrocarbon moiety which can be formed by a single or double 
chain of hydrocarbon or cholesterol, which provides self-association to form either 
micelles or liposomes in the presence of a helper lipid, such as 
1. Introduction 
7 
 
dioleylphosphatidylethanolamine (DOPE) (Cevher et al., 2012; De Laporte et al., 2006; 
Machado et al., 2014). 
 
 
 
 
 
 
 
 
 
 
Gene delivery systems based on cationic lipids are a promising approach because 
they are easy to mass-produce and less immunogenic than the viral vectors, however, 
their transfection efficiency is not as high as viral vectors. Gene transfer efficiency of a 
lipoplex depends on its structural and physicochemical properties, such as stability and 
size, and recent findings suggest that the low efficiency of these vectors could be related 
to a nonspecific immunogenic response or due to instability of these vectors in the 
presence of serum, which creates difficulties for in vivo applications. The charge ratio 
between cationic lipids and negatively charged DNA is also an important parameter for 
transfection efficiency, since lipoplexes with a high charge ratio, where number of 
positive charges are in excess, are more efficient than neutral lipoplexes (Chesnoy et al., 
2000). Positive charges on lipoplexes enhance their clearance from the circulation 
(Corsi et al., 2003). 
Liposomes, the most used lipid-based gene delivery system, are colloidal systems 
with spherical form and composed of aqueous core enclosed by natural or synthetic 
phospholipid bilayers. Liposomes are classified based on lipid bilayers such as 
unilamellar or multilamellar liposomes (Fig. 1.4) and in addiction to cationic lipids may 
further contain a neutral/helper lipid, such as DOPE and cholesterol, which destabilizes 
the endosomal membrane to facilitate lipid exchange and membrane fusion between 
liposomes and endosomal membrane (Cevher et al., 2012; Nayerossadat et al., 2012). 
They are used in gene delivery to the lung, spleen, kidney, liver, skin cells, among 
others, due to their low toxicity and immunogenicity (Cevher et al., 2012; Mishra et al., 
2011). 
Figure 1.3 - Example of a cationic lipid (adapted from (Chesnoy et al., 2000)). 
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Although they can be produced in large scale and effective at small doses 
(Machado et al., 2014), when compared with viral vectors, a major problem of cationic 
liposomes is the low transfection, which can be influenced by factors such as size, 
number of layers, surface charge, namely charge ratio between DNA and cationic lipid, 
presence of helper lipid or by the presence of serum. The inhibitory effect of serum can 
be overcome either by increasing the charge ratio or modifying liposome surface with 
hydrophilic polymers, such as polyethylene glycol (PEG), called hydration layer, to 
avoid protein interaction and hence prevent their aggregation upon contact with serum, 
thus, to increase their circulation lifetime in the blood and transfection efficiency 
(Cevher et al., 2012; Chesnoy et al., 2000; Muralidharan et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Polymer-based systems 
 
Gene delivery systems based on polymers offer some specific advantages over 
lipid-based systems. Complexes involving cationic polymers are smaller, more stable 
and less cytotoxic than those involving cationic lipids. Furthermore, polyplexes 
condense more DNA and the efficiency with which it bind and condense DNA, allows 
their protection during the intracellular transport (Buschmann et al., 2013; Corsi et al., 
2003; Mansouri et al., 2004). 
Figure 1.4 - Schematic representation of liposomal structures (adapted from (Mishra et al., 2011)). 
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Polymers/DNA complexes should protect negatively charged DNA from repulsion 
of the anionic cell surface, condense it into nano- or micro-structures for increased 
cellular internalization and once inside the cell protect it from nuclease degradation. In 
brief, three strategies have been used to produce polyplexes, either by electrostatic 
interactions, encapsulation or adsorption (Fig. 1.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The most common approach for polyplexes production is by electrostatic 
interactions, where polymer/DNA binding occurs between protonated amine groups 
present on polymers with negatively charged phosphate groups of DNA. This binding 
must occur at a sufficient nitrogen to phosphate charge ratio (N:P ratio), to promote 
slightly positively charged polyplexes formation and to avoid repulsions of negative cell 
surfaces (Wong et al., 2007). An ideal polyplex should compact anionic DNA as much 
as possible and be able to cross the cell membrane and protect the DNA inside the 
cytoplasm before it enters the nucleus, but then the polymer-DNA complexation should 
be weak enough to allow DNA release for transcription inside the nucleus (Yue et al., 
2013). 
Non-viral gene delivery systems based on polyplexes, have been considered a safe 
alternative to viral vectors due to their features of inducing relatively low toxicity, no 
significant immune responses, ability to be administered repeatedly to achieve long-
Figure 1.5 - Three main approaches to packaging DNA into polymer-based vectors: electrostatic 
interactions, encapsulation and adsorption (adapted from (Wong et al., 2007)). 
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term gene expression, easy preparation, biodegradability, flexibility in use, cell-type 
specificity after chemical conjugation of a targeting ligand, and have capacity to 
package large DNA plasmids (Tang et al., 2006). Therefore, inefficient delivery at the 
intracellular level (Gaal et al., 2011) and hence low transfection efficiency is the major 
challenge of polymer-based gene therapy. 
For a successfully nuclear delivery, polyplexes must efficiently enter the cells 
and pass through the intracellular space to the nucleus, overcome biological barriers 
such as plasma, endosomal and nucleus membrane (Yu et al., 2012). The properties of 
the complex, such as size, N:P ratio and kind of cationic polymer influence the extra 
and intracellular itinerary of the complex. High molecular weight polymers tend to form 
small and stable complexes, while complexes formed by low molecular weight 
polymers have lower cytotoxicity and higher ability of dissociation between DNA and 
cationic polymer, which increase transfection efficiency (De Laporte et al., 2006). 
Cationic polymers can be classified in two groups: synthetic polymers, such as 
polyethylenimine (PEI) and dendrimers, and natural polymers, such as chitosan (CS) 
and hyaluronic acid (HA). 
 
1.3 Synthetic polymers 
 
Synthetic polymers are the most commonly used non-viral gene delivery systems 
in gene therapy and PEI is one of the most effective and versatile polymer-based 
vectors. PEI is able to efficiently promote the DNA condensation, protecting DNA from 
degradation by DNases, and forming nanoparticles easily endocytosed by different cell 
types. PEI also has a strong buffering capacity at almost any pH because of the great 
number of primary, secondary and tertiary amino groups, which give PEI an 
opportunity to escape from the endosome (proton sponge effect). This polymer can be 
synthesized in its linear or branched form, with the linear form being the most efficient 
and with lower cytotoxicity (Nayerossadat et al., 2012). PEI, a non-biodegradable 
polymer, can be used with different molecular weights (MW) which is closely related to 
their cytotoxicity and their transfection efficiency (Tiera et al., 2006; Yue et al., 2013). 
PEI with MW of 25 kDa or higher, has been associated with high transfection 
efficiencies but increased cytotoxicity, while low MW PEI display much lower toxicity 
but almost no transfection efficiency (Corsi et al., 2003; Tang et al., 2006). Attaching 
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PEG to the surface of the particles, is a manner of decreasing the cytotoxicity and the 
non-specific interactions, increasing its half-life in the bloodstream (Corsi et al., 2003). 
Poly-L-lysine (PLL), is a biodegradable synthetic polymer which interact 
electrostatically with negatively charged DNA to form polyplexes, however, PLL with 
high MW exhibits cytotoxicity and tendency to aggregate and precipitate depending on 
the ionic strength, which can be ameliorated through PEGylation (Park et al., 2006). 
Compared with PEI, polyplexes formed by PLL are taken up into cells as efficiently as 
PEI polyplexes, however, with a lower transfection efficiency (Tiera et al., 2006), while 
poly[alpha-(4-aminobutyl)-L-glycolic acid] (PAGA), a derivative of PLL, has showed a 
significantly higher transfection efficiency than PLL with no measurable cytotoxicity 
detected (Park et al., 2006). 
Poly(2-dimethylaminoethyl methacrylate) (pDMAEMA) is a water-soluble 
cationic polymer which has primary and secondary amines that can facilitate 
complexation (De Laporte et al., 2006; Park et al., 2006). PDMAEMA is more effective 
than branched PEI and PLL due to their ability to condense DNA into small and 
positively charged particles which are able to transfect various cell types (Tiera et al., 
2006). 
Another approach is the use of dendrimers that are synthetic branched polymers 
with tendency to adopt a globular shape and consist of symmetrical branches projecting 
from a central core, with functional groups on their surface that can be used to bind 
DNA and form complexes termed dendriplexes. Dendriplexes protect DNA from 
nucleases and have high transfection efficiency with low cytotoxicity, however, 
transfection efficiency depends on the size, shape and number of primary amino groups 
on the surface of the polymer (Cevher et al., 2012; Tiera et al., 2006).  
Poly(amidoamine) (PAMAM) dendrimers were the first dendrimer family to be 
synthesized and characterized (Esfand et al., 2001), built from an ethylenediamine or 
ammonia core by addition, through stepwise polymerization process, of layers or 
generations of methacrylate and ethylenediamine. Cytotoxicity of PAMAM dendrimers 
increases with generation, however, is lower than high MW PEI and PLL polymers 
(Dufes et al., 2005). 
Dendrimers have been used in gene expression, immunodiagnostics and 
controlled and targeted delivery due to a large number of different molecules that can be 
conjugated to functional groups on the surface of the dendrimer (Cevher et al., 2012). 
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Polymers such as polyamides, polyamines, polyesters, among others, also are used to 
building dendrimers (Lee et al., 2005). 
 
1.4 Natural polymers 
 
Natural polymers have specific advantages over the most used gene delivery 
systems, the synthetic polymers, such as environmental responsiveness via degradation 
and remodeling by cell-secreted enzymes. Among natural polymers, collagen, gelatin, 
alginate and, described in more detail, CS and HA, have been used for gene delivery 
and are, in general, non-toxic, even in large doses, biocompatible, biodegradable and 
mucoadhesive (Dang et al., 2006). 
Collagen is the major insoluble fibrous protein in the extracellular matrix (ECM) 
(Zuber et al., 2015) and in connective tissue, and their structural and biochemical 
properties make it a promising polymer for gene delivery (Urello et al., 2014). Collagen 
is a non-toxic and low antigenic polymer, which can be easily combined with other 
materials, such as synthetic polymers, forming DNA complexes at low pH due to rapid 
aggregation and its low stability in serum at neutral pH (Jun Wang et al., 2004; Zuber et 
al., 2015). Collagen has superior biocompatibility when compared with gelatin (Zuber 
et al., 2015). 
Gelatin, a denatured form of collagen, obtained by acid and alkaline processing of 
collagen (Dang et al., 2006; Malafaya et al., 2007), contains many glycine, proline and 
4-hydroxyproline residues and have been used for pharmaceutical and medical 
applications due to its inexpensiveness and high availability, furthermore, is highly 
biocompatible and biodegradable in a physiological environment (Malafaya et al., 2007; 
Santoro et al., 2014). Gelatin nanoparticles maintain plasmid DNA structure, protecting 
it from nucleases degradation, and improve the transfection efficiency upon intracellular 
delivery (Xu et al., 2012). 
Alginate is a naturally occurring anionic polymer, typically obtained from marine 
brown algae and bacterial species as Azotobacter vinelandii and several Pseudomonas 
species. This linear polymer is composed by regions of D-mannuronic acid, regions of 
L-gluluronic acid and regions of both, depending on the natural source. Alginate has 
been used in biomedical applications due to their properties as biocompatibility, low 
toxicity, good mucoadhesive and slight gelation by addition of divalent cations as Ca2+, 
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forming hydrogels widely used in wound healing, drug delivery and tissue engineering 
(Lee et al., 2012; Malafaya et al., 2007). 
 
1.4.1 Chitosan 
 
Chitosan is a cationic polymer obtained by deacetylation of chitin, which can be 
used at different degrees of deacetylation, usually between 70% and 95%, and 
composed of two subunits: D-glucosamine and N-acetyl-D-glucosamine, which are 
linked by a (1-4) glycosidic bond (Fig. 1.6) (Dang et al., 2006; Malafaya et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chitosan has several advantageous qualities in comparison with other non-viral 
vectors, such as their biocompatibility, biodegradability, non-toxicity and non-
antigenicity (Chae et al., 2005; Grenha et al., 2005), making it useful and widely 
employed in several biomedical fields such as gene delivery, tissue engineering and 
drug delivery (Chae et al., 2005; Huang et al., 2005). Due to their mucoadhesive 
properties, CS-based gene delivery systems have been successfully applied in several 
mucosal routes, such as the nasal and ocular (Buschmann et al., 2013; Dang et al., 2006; 
Grenha et al., 2005). 
Figure 1.6 - Schematic representation of chitosan structure (adapted from (Agirre et al., 2014)). 
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Furthermore, CS is a weak base with a pKa value of the D-glucosamine residue of 
about 6.2-7.0, making it a pH responsive polymer, which is insoluble at neutral and 
alkaline pH. At pH below physiological pH, the primary amines in the CS backbone 
become protonated making it soluble in acidic medium (Agirre et al., 2014; Opanasopit 
et al., 2011). These positively charged amine groups enable CS to bind and package 
large molecules of DNA, condensing it into particles (Kim et al., 2003; Weecharangsan 
et al., 2008) and avoiding its degradation by DNases. The interaction of CS-DNA 
complex is driven mainly by electrostatic interactions between the positively charged 
amino groups of CS and the negatively charged phosphates groups of DNA (Tiera et al., 
2006). 
Several particle preparation methods can be used to prepare CS polyplexes, as the 
direct mixing of CS over DNA pipetting up and down or a more vigorous vortex 
agitation, which can be performed at room temperature or 50-55ºC, or even factors such 
as presence or absence of salt, in a very dilute or concentrated regime, with equal or 
different volumes of CS and DNA solutions, among other factors (Agirre et al., 2014; 
Buschmann et al., 2013). However, regardless of the mixing conditions used, an excess 
of CS conferring positive charge to the polyplex seems to be the crucial parameter in all 
formulations that have successfully transfected cells in vitro (Buschmann et al., 2013). 
The size of polyplexes depends of MW of CS, plasmid concentration and N:P ratio of 
CS/DNA, which may affect the blood circulation time and the cellular uptake and thus 
transfection efficiency (Tiera et al., 2006). 
Transfection efficiency referred as ability of complex CS/DNA to induce gene 
expression (Buschmann et al., 2013) is influenced by several factors, including the 
degree of deacetylation and MW of CS, stoichiometry of complex, plasmid 
concentration, N:P ratio, serum concentration and pH of medium (Dang et al., 2006; 
Huang et al., 2005; Ishii et al., 2001; Opanasopit et al., 2011; Sajomsang et al., 2009; 
Weecharangsan et al., 2008). Furthermore, transfection efficiency of CS/DNA 
complexes is cell type-dependent (Dang et al., 2006; Mansouri et al., 2004; Sajomsang 
et al., 2009), as seen in several in vitro transfections that have been reported in various 
cell types, such as human embryonic kidney cells (HEK293), human lung 
adenocarcinoma epithelial cells (A549), B16 murine melanoma cells, COS-1 and HeLa 
cells. The cellular uptake depends on cellular membrane composition that varies among 
cellular types and may facilitate or hinder the binding of the complex and their 
internalization (Corsi et al., 2003). 
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The MW is one of the most important factors, because it also influences the 
binding affinity between CS/DNA and dissociation of DNA from the complex (Agirre 
et al., 2014). The binding affinity defines the ability of the polymer to complex, release 
and protect the DNA from degradation, as well as polyplex stability (Agirre et al., 2014; 
Buschmann et al., 2013), and hence the transfection efficiency. A balance between the 
DNA protection and intracellular DNA unpacking is necessary, because polyplexes 
must be stable enough to retain the DNA but also must be able to release the DNA once 
inside the cell (Agirre et al., 2014). Low MW CS tends to form less stable polyplexes 
leading to a more efficient intracellular release, while release of DNA by high MW CS 
is limited, due to high stability and strong affinity of polymer to DNA (Agirre et al., 
2014; Dang et al., 2006). 
Chitosan can be modified in order to improve its solubility and stability allowing 
an increased circulation lifetime (Agirre et al., 2014) or to increase proton sponge 
capacity improving endosomal escape (Buschmann et al., 2013), among others. These 
modifications can be achieved grafting certain molecules or polymers on the C2 amine, 
the C6 hydroxyl or both groups, through of PEGylation, quaternization or glycolyzation 
(Agirre et al., 2014; Buschmann et al., 2013; Chae et al., 2005). Furthermore, addition 
of a polyanion, as HA, is another approach to increase transfection efficiency of 
CS/DNA complexes, since incorporation of HA destabilizes the interactions between 
CS and DNA, facilitating DNA release and improving, thus, transfection efficiency of 
complexes (Buschmann et al., 2013; He et al., 2010). 
 
1.4.2 Hyaluronic acid 
 
Hyaluronic acid, also called hyaluronan, is a high MW anionic biopolymer 
composed of two subunits: D-glucuronic acid and N-acetyl-D-glucosamine linked by a 
glycosidic bond (Necas et al., 2008; Oh et al., 2010). HA can be easily produced in 
large scale from bacterial sources through microbial fermentation (Becker et al., 2009; 
Ito et al., 2006) being synthesized by hyaluronan synthases and degraded by 
hyaluronidases (Cho et al., 2011). HA is abundant in the ECM but can be found also in 
the synovial fluid, skin, lung, intestine, umbilical cord, vitreous of human eye and blood 
(Necas et al., 2008; Oh et al., 2010). The biological functions of HA include regulation 
of tissue hydration and water transport, maintenance of the elastic viscosity of joint 
synovial and eye vitreous fluid, among others, lubrication, control immune response, 
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cell proliferation and migration, wound healing, among others (Becker et al., 2009; 
Necas et al., 2008; Raemdonck et al., 2013). 
HA has been used in drug delivery, tissue engineering, ocular and plastic surgery 
and gene delivery (Boeckel et al., 2014; Oh et al., 2010) due to its viscoelastic, 
mucoadhesive and shock-absorption properties, as well as, their non-immunogenicity, 
non-antigenicity, biocompatibility and biodegradability (Boeckel et al., 2014; 
Contreras-Ruiz et al., 2011; Raemdonck et al., 2013). As described above, HA have 
been used in ternary complexes as an anionic additive incorporated into existing gene 
delivery systems, such as CS/DNA complexes, because HA can coat complexes without 
disrupting their structures. Moreover, HA protects complexes against serum proteins 
and blood cells by decreasing nonspecific interactions (Ito et al., 2006) and improves 
transfection efficiency of complexes by a loosening effect of HA on the tightly 
compacted DNA molecule allowing the access of transcription factors to DNA (Ito et 
al., 2010). HA can be used also as a signaling molecule that interacts with specific cell 
surface receptors, as cluster determinant 44 (CD44), receptor for hyaluronate – 
mediated motility (RHAMM), HA receptor for endocytosis (HARE) and lymphatic 
vessel endothelial hyaluronan receptor-1 (LYVE-1) (Raemdonck et al., 2013), leading 
to intracellular signaling, influencing cell migration, proliferation and gene expression 
(Becker et al., 2009; Necas et al., 2008). These receptors are present on the cell surface 
and extracellular matrix of some specific tissues, such as liver and kidney, and most of 
cancer tissues (Oh et al., 2010; Park et al., 2010). Furthermore, HA has several 
functional groups available for chemical conjugation that have been successfully used in 
conjugation reactions with drugs (Plattt et al., 2008). 
 
1.5 Extracellular and intracellular barriers 
 
For efficient gene transfection, non-viral vectors need to overcome many barriers 
as cell binding and internalization, escape from endosomes and nuclear translocation 
(Ito et al., 2006). To date a variety of polyplexes have been developed taking into 
account several factors, such as non-specific interactions either with serum components 
or with negatively charged cell surface (De Laporte et al., 2006). Because, at a cellular 
level, the first obstacle encountered by polyplexes are biological fluids, which can affect 
their stability and might cause aggregation or degradation of complexes. Once in 
proximity of a cell, to achieve gene expression, polyplexes need to bind to the cell 
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surface. This cell attachment can occur through non-specific electrostatic interactions 
between positive charge of the polyplexes and negative charge of the cell surface or by 
receptor ligands added to the polyplexes, to target specific cell types. Cellular uptake is 
achieved mainly by endocytosis and can occur, at least, through five different pathways: 
phagocytosis, macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated 
endocytosis and clathrin- and caveolae-independent endocytosis, which depend on the 
particle size and cell type. 
Upon cellular entry, the intracellular itinerary of endocytic vesicles depends on 
the pathway by which polyplexes were internalized, including recycling back to the 
surface cell, transformation into acidic degradative vesicles (lysosomes) or delivery to 
an intracellular organelle (e.g. reticulum endoplasmic or Golgi apparatus). However, 
polyplexes must escape efficiently of endocytic vesicles to avoid enzymatic degradation 
within lysosomal compartments. The proton sponge effect is the most studied escape 
from endosomes and depends on the buffering capacity of the polymer (Agirre et al., 
2014; Wong et al., 2007). The proton sponge effect is based on acidification of endo-
lysosomes by pumping of protons, leading to an influx of Cl- that cause an increase of 
osmotic pressure and water absorption, resulting on endo-lysosome swelling. The 
combination of increased osmotic pressure and endo-lysosome swelling leads to its 
destabilization, rupture and release of its content into the cytoplasm before its 
degradation (Tiera et al., 2006; Yue et al., 2013). 
Following escape of the endo-lysosomal pathway, polyplexes must be 
transported to the nucleus and internalize DNA across the nuclear membrane for its 
subsequent transcription (Agirre et al., 2014; De Laporte et al., 2006). A balance 
between DNA protection and intracellular DNA unpacking must exist on polyplexes, 
once high binding affinity between polymer and DNA can hamper the release of DNA 
and, hence its transfection efficiency (Agirre et al., 2014). Finally, DNA released from 
polyplexes can enter the nucleus by 1) passive diffusion, where DNA enters the nucleus 
during cell division when nuclear membrane is temporarily disintegrated or by 2) active 
transport, where DNA enters the nucleus via nuclear pore complexes (NPCs) present on 
the nuclear membrane (Fig. 1.7) (Tiera et al., 2006).  
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NPC allows passive diffusion of small molecules (diameter ≤ 9 nm or MW ≤ 45 
kDa), while large molecules, as polyplexes used for gene delivery (≥ 100 nm), are 
transported actively through NPC by specific nuclear proteins, as importins, namely 
importin-α and importin-β (van Gaal et al., 2011; Yue et al., 2013). Importins can bind 
to the polyplexes by recognition of specific sequences, called nuclear localization 
signals (NLS), previously attached to these, which have been used to improve nuclear 
import and hence the efficiency of gene expression (Boulanger et al., 2005). 
 
1.6 Nuclear localization signals 
 
NLS are cationic peptides sequences that consist of either one or two stretches of 
highly basic amino acids of arginine/lysine, which are attached to DNA complexes, as 
polyplexes, and recognized by importins that direct their transport into the nucleus 
(Wong et al., 2007; Yue et al., 2013). NLS attached to polyplexes, can bind directly to 
importin-β or through the adapter protein, importin-α, which in turns bind to importin-β 
and form a complex. The resulting complex binds to the NPC, through of association 
with its cytoplasmic filaments, and is translocated through the pore to the nucleus. 
Finally, the complex dissociates and importins are recycled back to the cytoplasm and 
Figure 1.7 - Itinerary of gene delivery systems based on polymers. I) electrostatic interactions between 
positively charged polymer and negatively charged DNA to polyplex formation and subsequent entry into 
cells by endocytosis, II) once within the endocytic vesicles, polyplexes can be degraded on lysosomes or 
III) escape from endosome by proton sponge effect. IV) Latter, DNA is dissociated of polymer and V) 
should be able to cross nuclear membrane for its subsequent transcription and VI) transduction (adapted 
from (Wong et al., 2007)). 
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are available for a next import cycle (Cartier et al., 2002; Görlich, 1997; Keller et al., 
2003; van Gaal et al., 2011). Complex formation and dissociation is achieved by an 
energy-dependent mechanism involving Ras-related nuclear protein guanosine 
triphosphate (RanGTP) and other proteins (Fig. 1.8) (Boulanger et al., 2005; Cartier et 
al., 2002; Cherezova et al., 2011; Ciolina et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 - Nuclear import mediated by importin-α and importin-β. Importin-β recognizes NLS-
containing polyplex or protein and binds via importin-α adapter. Complex is translocated through the 
NPC into nucleus and then is dissociated by an energy-dependent mechanism mediated by RanGTP. 
Importin-β are recycled to the cytoplasm complexed with RanGTP and importin-α is exported with a 
RanGTP/CAS (cellular apoptosis susceptibility protein) complex. Finally, GTP hydrolysis dissociate the 
export complexes and release the importins for another nuclear import cycle (adapted from (Conti et al., 
2006)). 
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The use of NLS for non-viral gene therapy has been widely investigated due to 
inefficient transfer of DNA from the cytoplasm to the nucleus that limits gene 
expression, mainly in post-mitotic and quiescent cells, where there is no disintegration 
of nuclear membrane (Boulanger et al., 2005; Bremner et al., 2004; Hu et al., 2012). 
This approach was first used by virus to efficiently integrate their genetic material into 
the host DNA (Zanta et al., 1999), and to date, NLS have been used in several studies 
with the goal of overcoming gene cytoplasmic degradation through an effective 
transport into the nucleus and, hence, improve nuclear delivery of DNA and, thus, 
increase gene expression (Boulanger et al., 2005; Bremner et al., 2004; Hébert, 2003). 
However, size and type of DNA (linear or plasmid), method used in the incorporation of 
NLS (covalent or non-covalent attachment of NLS to DNA or polymer), type of 
polymer used, among others, are some of several factors that influence the nuclear 
transport of DNA (Opanasopit et al., 2009; Wong et al., 2007). Furthermore, the type of 
NLS used in non-viral gene therapy can be monopartite or bipartite. Monopartite NLS 
can be characterized by a cluster of basic residues with a general sequence of 
K(K/R)X(K/R), as NLS derived from simian virus 40 (SV40) large T antigen, the NLS 
most used in gene therapy (PKKKRKV). While bipartite NLS can be characterized by 
two clusters of basic residues separated by 10-12 neutral residues, with a general 
sequence of (K/R)(K/R)X10-12(K/R)3/5, where at least 3 of 5 consecutive residues are 
arginine or lysine (Cherezova et al., 2011; Cokol et al., 2000; Marfori et al., 2011; van 
der Aa et al., 2005), as NLS derived from endogenous Insulin-like growth factor 
binding-3 (IGFBP-3) and -5 (IGFBP-5) (Schedlich et al., 2000). 
 
1.6.1 IGFBP-3 and IGFBP-5 
 
Insulin-like growth factor binding proteins (IGFBPs) are a family of six 
mammalian multifunctional proteins (Baxter, 2001; Hwa et al., 1999), which are 
involved in regulation and transport of insulin-like growth factors, IGF-I and IGF-II, in 
the circulation (Baxter, 2001; Ständker et al., 1998). IGFBPs can inhibit or stimulate 
cell growth and cell differentiation through regulation of binding of IGFs to type I IGF 
receptor (Schedlich et al., 2000). Furthermore, several studies have reported IGF-
independent cellular activity, to IGFBP-3 (Butt et al., 2000; Cohen et al., 1997) and 
IGFBP-5 (Berfield et al., 2000; Miyakoshi et al., 2001), as their capacity of inducing 
nuclear transport (Hwa et al., 1999; Schedlich et al., 2000; Wang et al., 2014). Site-
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specific mutagenesis has recognized that C-terminal region of IGFBP-3 and IGFBP-5 
(Table 1.1), contain a domain with strong homology with bipartite NLS sequence 
(Baxter, 2001; Hwa et al., 1999; Schedlich et al., 2000). Mutations in this sequence 
leads to reduction or even to abolition of nuclear accumulation (Iosef et al., 2008; 
Schedlich et al., 2000), suggesting that this 18-amino acid region of IGFBP-3 and 
IGFBP-5 (Table 1.1) is essential and sufficient for nuclear uptake of the binding 
proteins and nuclear accumulation of IGFBP-3 and IGFBP-5 in a several cell lines 
(Baxter, 2001; Hwa et al., 1999; Schedlich et al., 2000). 
 
 
Table 1.1 - Derived NLS sequences of C-terminal region of IGFBP-3 and IGFBP-5. 
Peptide Sequence 
IGFBP-3 215KKGFYKKKQCRPSKGRKR232 
IGFBP-5 201RKGFYKRKQCKPSRGRKR218 
 
 
These IGFBP peptides were already used to successfully deliver heterologous 
proteins, such as GST (Goda et al., 2008), however, to our knowledge, they were never 
used for gene delivery. Taking into account their properties of nuclear uptake and 
accumulation of the binding proteins, these peptides (Table 1.1) may be considered 
good candidates for gene therapy, and the development of gene delivery systems where 
they can be incorporated could be potential carriers for nucleus-targeting gene delivery. 
 
 
1.7 Aims 
 
For an efficient gene delivery, several barriers need to be overcome and the 
nuclear import is considered the major limiting step in the development of effective 
non-viral gene delivery systems. 
In this context, this work has as main aim to characterize and optimize several 
non-viral gene delivery systems based on natural polymers, as CS and HA. To 
overcome the nuclear barrier, incorporation of NLS derived of IGFBP peptides, an 
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endogenous NLS, to the polyplexes formulation is one of the strategies that can be used 
in order to enhance the internalization of the DNA in the nucleus. 
Taking this into account, three strategies to incorporate IGFBP peptides were 
tested, namely, co-administration, covalent ligation to CS polymer and co-complexation 
of IGFBP peptides into polyplexes. Moreover, a second polymer, HA, was incorporated 
into polyplexes and co-complexed with IGFBP peptides. 
The polyplexes were extensively characterized regarding their size, polydispersity, 
zeta potential and efficiency of DNA complexation. The effectiveness of polyplexes 
was evaluated through in vitro transfection assays using HEK293T cell line. 
Furthermore, analysis of the cytotoxicity of IGFBP peptides was carried out in 
HEK293T cells. 
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2.1 Materials 
 
2.1.1 Plasmids 
 
During this study, three plasmids (Fig. 2.1) were used: 
  pAAV2,1CMVeGFP3, encoding the enhanced green fluorescence protein 
(eGFP), driven by the cytomegalovirus (CMV) promoter and conferring ampicillin 
resistance, which was kindly provided by Dr. Jean Bennett (University of Pennsylvania, 
USA) and used in all polyplexes. 
  pCMVIGFBP-3 and pCMVIGFBP-5, driven by the CMV promoter and 
conferring kanamycin resistance, were used to encode the NLS derived of IGFBP 
peptides, respectively (Table 1.1), which contain a histidine tag at the N-terminal. These 
plasmids were previously constructed by S. Calado (unpublished data). 
The plasmids were amplified in Top10 E.coli bacteria and extracted using a 
Plasmid Maxi kit (Qiagen, USA), according to the manufacturer’s instructions. Later, 
plasmids were dissolved in TE buffer and their concentration was determined at 260nm 
using a NanoDrop 2000c spectrophotometer (Thermo Scientific, USA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.1 - Schematic representation of the structure of plasmids. (A) pAAV2.1CMVeGFP3 used for 
expression of GFP (B) pCMVIGFBP-3 used to encode IGFBP-3 peptide and (C) pCMVIGFBP-5 used to 
encode IGFBP-5 peptide. AmpR and KanR are genes for resistance to ampicilin and kanamycin, 
respectively. 
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2.1.2 Cell line and cell culture 
 
For the in vitro assays, the HEK293T cell line was used, which is a cell line 
widely used in transfection assays because of their ease of transfection (kindly provided 
by Dr. Guilherme Ferreira, University of Algarve, Portugal). Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM), containing 10% fetal bovine serum 
(FBS), 1% glutamine and 1% penicillin/streptomycin solution, and maintained at 37°C 
under a 5% CO2 atmosphere. When 70-80% of confluence was reached, the cells were 
trypsinized with trypsin-EDTA, and transferred to new culture flasks. All cell culture 
reagents were acquired from Sigma-Aldrich (St. Louis, MO/USA). 
 
2.1.3 Polymers 
 
Ultrapure chitosan CL 113 (CS), with MW of 80 kDa and degree of deacetylation 
of 83%, was purchased from Novamatrix (FMC BioPolymer AS, Norway). Hyaluronic 
acid (HA), with MW of 132 kDa, was purchase from Lifecore Biomedical Inc. (USA). 
Polymer solutions of 1 mg/ml were prepared dissolving the polymer in milliQ water, 
and the pH of the solutions was adjusted to 5.5 with sodium hydroxide. The solutions 
were sterile filtered through a 0,2 m filter. 
All other reagents were acquired from Sigma-Aldrich (St. Louis, MO/USA). 
 
 
2.2 Methods 
 
2.2.1 Bacterial transformation 
 
For bacterial transformation, aliquots of competent bacteria (E.coli TOP 10) were 
thawed and kept on ice. Then, 30 ng of plasmid (pCMVIGFBP-3 and pCMVIGFBP-5, 
respectively) were added to 100 µl of competent bacteria suspension and keep on ice for 
15 minutes (min), followed by a heat shock at 42ºC for 90 seconds (sec). Posteriorly, 
300 µl of S.O.C medium were added (containing 98% of S.O.B medium (triptone, yeast 
extract and NaCl), 1% of Mg2+ and 1% of glucose) and incubated the bacterial 
suspension at 37ºC, 180 revolutions per minute (rpm) for 30 min. Then, 100 µl of 
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transformed bacteria were spread in a pre-warmed LB agar plates containing kanamycin 
(30 µg/ml), and incubated overnight at 37°C. 
 
2.2.2 IGFBP peptides extraction 
 
The IGFBP peptides were extracted from the bacteria using the B-Per 6xHis 
Fusion Protein Purification Kit (Thermo Scientific, USA), according to manufacturer’s 
instructions, and quantified by Bradford method (Bradford, 1976). 
Thereafter, the peptides were dialyzed against 10 mM HCl solution for 6 hours 
and then against milliQ water, for 12 hours, on dialysis tubing with MW cut-off 2 kDa 
(Sigma-Aldrich, St. Louis, MO/USA). After dialysis, the peptide solutions were frozen 
at -80ºC and concentrated by sublimation in a vacuum pump. Their concentrations were 
determined by measurements at 280 nm (Kumar et al., 2013). 
 
2.2.3 Polyplexes preparation 
 
2.2.3.1 CS polyplexes 
 
Several research groups have worked in the optimization of CS-based vectors, 
suggesting that the mixing technique of CS with DNA and the incubation conditions 
influence the final gene expression (Lavertu et al., 2006). Different methods, mainly 
driven by electrostatic interactions, adapted from Mao et al., 2001, were used to prepare 
the polyplexes. All polyplexes were prepared with an excess amount of CS to DNA, 
250 µg of CS to 26.5 µg of DNA (N:P ratio of 15:1). All of nanoparticles were used for 
transfection assays without purification. 
 
 CSNa2SO4 
DNA was diluted in a sodium sulfate solution (25 mM) and an equal volume of 
CS solution was preheated to 55°C for 5 min, and quickly mixed together, placed on ice 
for 30 min and stored at 4°C (Fig. 2.2). Different concentrations of IGFBP peptides; 10, 
25, 50, 100 and 150 µg for IGFBP-3 and 10, 25 and 50 µg for IGFBP-5; were co-
administrated later at the time of transfection in the cell culture well. 
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 CS 
In order to evaluate if polyplexes were affected by the presence of salts, sodium 
sulfate solution was removed, and polyplexes were prepared by adding the DNA 
directly to the CS solution (Fig.2.3). 
 
 
 
 
 
 
 
 CS3 and CS5 
The total amount of IGFBP peptides was either added to the CS solution (T) or 
divided into equal parts and added to both the CS solution and DNA solution (S) and 
quickly mixed together as depicted in Fig. 2.4 and 2.5, respectively. 
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Figure 2.2 - Schematic representation of CSNa2SO4 polyplexes preparation. 
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Figure 2.3 - Schematic representation of CS polyplexes preparation. 
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Figure 2.4 - Schematic representation of CS3 and CS5 polyplexes preparation, where the total amount of 
IGFBP peptides was added to the CS solution (T). 
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Figure 2.5 - Schematic representation of CS3 and CS5 polyplexes preparation, where the total amount 
was divided into equal parts and added to both the CS solution and DNA solution (S). 
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 15:1CS3 and 15:1CS5 
For formulations 15:1CS3 and 15:1CS5, we chose a fixed peptide concentration of 
100µg. In order to evaluate differences in complexation, polyplexes were prepared 
considering the total amount of amine groups, including peptides and polymer, at a 
IGFBP-3 or -5/CS:DNA (N:P ratio) of 15:1, and the amount of CS solution was 
adjusted. This formulation was prepared the same way as previously described (Fig. 2.4 
and Fig. 2.5). 
 
 CSedac3 and CSedac5 
In this formulation, a one and a half molar excess (relative to the carboxylic acid 
groups in peptides) of N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
(EDAC) were added to 100µg of IGFBP peptides, respectively, and stirred at 4˚C for 
24h (Fig. 2.6). Then, the mixture was added to polyplexes previously prepared 
(described above, Fig. 2.3) and stored at 4°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3.2 HA polyplexes 
 
 CSHA3 and CSHA5 
Polyplexes with HA polymer were prepared using a CS:HA weight ratio of 5:1, 
and a CSHA:DNA N:P ratio of 15:1, these ratios were chosen based on previous work 
(Oliveira et al., 2014). The total amount of IGFBP peptides, at different concentrations, 
respectively, was divided into equal parts and was added to CS solution and HA, milliQ 
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Figure 2.6 - Schematic representation of CSedac3 and CSedac5 polyplexes preparation. 
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H2O and DNA solution, preheated to 55˚C for 5 min, quickly mixed together and stored 
at 4˚C (Fig. 2.7). 
 
 
 
 
 
 
 
 
 
2.2.4 Polyplex characterization 
 
Freshly prepared samples were diluted in milliQ H2O and polyplex size 
measurements were performed by dynamic light scattering (DLS), at 25˚C with a 
detection angle of 173º, using a Zetasizer Nano ZS (Malvern Instruments, UK). The 
zeta potential (surface charge) was measured with laser Doppler velocimetry at 25˚C on 
the same instrument. After characterization of polyplexes, preparations were stored at 
4ºC, to avoid DNA denaturation and complex dissociation. 
 
2.2.5 Polyplex complexation 
 
The DNA complexation efficiency in the polyplexes was assessed by a retardation 
assay using agarose gel electrophoresis. Agarose gels with 1% (W/V) agarose in TAE 
buffer with GreenSafe® Premium (NZYtech, Portugal) were prepared. The polyplexes 
were loaded in each well and the electrophoresis was carried out for approximately 60 
min at 90mV. The samples were visualized under UV light. 
 
2.2.6 Cell viability evaluation 
 
To evaluate the cytotoxicity of IGFBP-3 or IGFBP-5 peptides on HEK293T cells, 
we performed a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay. Cells were seeded in a 48-well plate at a density of 15 000 cells per well in 500µl 
of DMEM and allowed to grow for 24h, at 37°C under 5% CO2 atmosphere. After this 
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Figure 2.7 - Schematic representation of CSHA3 and CSHA5 polyplexes preparation. 
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time, medium was removed and five different concentrations of IGFBP-3 and IGFBP-5 
peptides (10, 25, 50, 100 and 150 µg) were tested by adding peptides to 500 µl of free 
DMEM. As in the transfection assay, after 5 hours, the medium was changed to DMEM 
with FBS, and cells were incubated up to 72h, at 37°C under 5% CO2 atmosphere. 
At the end of the incubation time, the medium was removed and 25 µl of MTT 
solution was added (5 mg/ml in phosphate buffered saline (PBS)) and the cells 
incubated for 4 hours. For formazan crystals solubilization, formed in living cells, 250 
µl of HCl/Isopropanol (0,04 N HCl in isopropanol) was added to each well. After one 
hour, the absorbance was measured on a microplate reader (Tecan Infinite M200, USA) 
at 570 nm, for formazan solution, and 630 nm, for cellular debris. Non-treated cells 
were used as positive control, and cells treated with latex extract were used as negative 
control, and cell viability was calculated using the following equation: 
Absorbance samples = absorbance at 570 nm - absorbance at 630 nm 
Cell viability (%) = (absorbance samples ÷ absorbance positive control) × 100 
 
2.2.7 In vitro transfection assays 
 
Cells were seeded at a density of 200 000 cells per well in a 6 well culture plates 
with DMEM supplemented with FBS, 24h prior to transfection, at 37°C under a 5% 
CO2 atmosphere. We performed the transfection using 1 µg of DNA per well and 
FuGENE® HD (Promega, USA) as positive transfection control, according to the 
manufacturer’s instructions. Non-transfected cells were used as negative transfection 
control. 
Polyplexes, prepared as describe above, were added to the cells and incubated in 
FBS free medium for 5h. After 5 h, the medium was changed to complete medium and 
cells were analyzed for transfection efficiency after 72h. All polyplexes were added to 
the cells on a single step, except the CSNa2SO4, where the polyplexes were added to the 
cells and then different concentrations of IGFBP-3 or IGFBP-5, respectively, were 
added (Fig. 2.8). 
All transfection experiments were performed in triplicate. Transfected cells were 
visualized, 48h and 72h after transfection, using a fluorescence microscope (Axiovert 
40 CFL, Zeiss) in order to evaluate GFP expression. 
 
  
2. Materials and Methods 
31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.8 Transfection efficiency evaluation by flow cytometry 
 
Transfection efficiency was evaluated quantitatively by flow cytometry. Cells 
were washed three times with PBS, the supernatants were discarded, and the cells were 
re-suspended in PBS and placed in specific tubes to be analyzed in the flow cytometer 
(FACScalibur, BD Biosciences, USA), for analyze of GFP expression. A total 50000 
events were counted for each sample. 
 
2.2.9 Statistical analysis 
 
Statistical analysis was performed using a GraphPad Prism 6 software, and data 
were analyzed using ANOVA test (one-way ANOVA) and multiple comparisons tests 
using a confidence interval of 95% and considering P<0.05 value as significant. 
 
  
Figure 2.8 - Schematic representation of transfection assays. All polyplexes were added directly to the 
cells, except CSNa2SO4, which were co-administrated with IGFBP peptides, respectively. 
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3.1 Polyplexes characterization 
 
A positive surface charge is required on polyplexes for efficient cellular uptake, 
since cell entry occurs by non-specific electrostatic interactions between the positively 
charged polyplexes and the negatively charged cell surface (Tros de Ilarduya et al., 
2010). In order to avoid repulsion by the negative cell surface, a N:P ratio of 15:1 was 
chosen to promote the formation of positively charged polyplexes. Parameters as N:P 
ratio, molecular weight, mixing technique, among others, have been widely investigated 
on CS/DNA complexes (Buschmann et al., 2013; Chae et al., 2005; Ishii et al., 2001; 
Mao et al., 2001; Opanasopit et al., 2009), and described as factors that influence the 
binding affinity between CS/DNA, size and zeta potential of polyplexes, cellular uptake 
and dissociation of DNA, and thus, transfection efficiency (Agirre et al., 2014; 
Buschmann et al., 2013; De Laporte et al., 2006). 
The mixing technique of the CS solution and DNA solution used was adapted 
from Mao et al., 2001, where polyplexes were prepared by solubilization of DNA in a 
Na2SO4 solution, used as desolvating reagent, and mixed with CS solution. Both 
solutions were preheated at 55ºC to allow polyplexes formation with less aggregation 
(Mao et al., 2001). Polyplexes were formed as result of electrostatic interactions 
between positively charged amine groups of CS and negatively charged phosphate 
groups of DNA, and posteriorly, Zetasizer measurements were made to evaluate their 
size, polydispersity index (PdI) and zeta potential. 
This preparation method of polyplexes yielded homogeneous preparations, with 
PdI below 0.3, and mean size of 285.85 ± 56.50 nm (Table 3.1). Regarding zeta 
potential, positively charged polyplexes were prepared, with mean values of zeta 
potential of 15.45 ± 0.21 mV. These polyplexes were prepared without IGFBP peptides, 
and used, later, on transfection assays, where several concentrations of IGFBP-3 and 
IGFBP-5 peptides were co-administrated at the time of transfection, respectively, as 
described above. 
 
Table 3.1 - Size, PdI and zeta potential of CSNa2SO4 polyplexes. 
Polyplex Z-average size (nm) PdI Zeta potential (mV) 
CSNa2SO4 285.85 ± 56.50 0.12 ± 0.05 15.45 ± 0.21 
Values are presented as mean ± S.D. 
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To evaluate if sodium sulfate salts affected polyplexes, this was removed from the 
polyplexes preparation. Moreover, several concentrations of IGFBP peptides were co-
complexed with polyplexes, where the total amount of IGFBP peptides was divided into 
equal parts and added to both the CS solution and DNA solution, as described above. 
Polyplexes were characterized regarding their size, PdI and zeta potential, as depicted in 
Fig. 3.1. 
According to Mao et al., 2001, concentrations up to 25 mM of sodium sulfate do 
not significantly affect the mean size of polyplexes, however, CS polyplexes, without 
sodium sulfate and IGFBP peptides, yielded particles with an increased mean size of 
729.27 ± 116.77 nm and an increased positive charge with a mean zeta potential of 
27.17 ± 10.43 mV. These results suggest that sodium sulfate has a role on the 
entanglement of CS with DNA, which results in polyplexes with smaller size and lower 
positive surface charge. 
Regarding polyplexes prepared with several concentrations of IGFBP peptides, 
statistical differences were found for the mean size of polyplexes co-complexed with 
concentrations of IGFBP-5 peptides between 50 µg and 250 µg, when compared with 
polyplexes without IGFBP peptides (Fig. 3.1). However, despite not having found 
statistical differences between polyplexes prepared with different concentrations of 
IGFBP-3 peptides and polyplexes without IGFBP peptides, size similarities were found 
when comparing them to polyplexes with IGFBP-5 peptides. This preparation method 
of polyplexes produced less homogeneous solutions, with PdI above 0,3, which can be 
result of some aggregation. Regarding to zeta potential, mean values of surface charge 
increased, as expected, since the NLS sequences used (Table 1.1) are rich in basic 
amino acids resulting on an increase of the overall positive charges and, hence, an 
increase of surface charge of polyplexes. These results indicate that addition of IGFBP 
peptides to polyplexes influenced their physical properties, namely their size and zeta 
potential, as previously reported (Opanasopit et al., 2009). 
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Since the mixing method can influence parameters such as polyplex size, 
(Buschmann et al., 2013), to evaluate if dividing (S) or adding the total amount of 
IGFBP peptides directly to CS solution (T), had a significant impact on polyplexes 
formation, we decided to select the IGFBP concentration of 100 µg, which presented a 
better transfection efficiency (described in the next section, Fig. 3.11). We characterized 
the produced polyplexes (Table 3.2) and compared them with CS (S) formulation with 
100 µg of IGFBP peptides (Fig. 3.2). 
 
Table 3.2 - Composition, size, PdI and zeta potential of CS3 and CS5 (T) polyplexes. 
Polyplex IGFBP (µg) Z-average size (nm) PdI Zeta potential (mV) 
CS3 (T) 
100 µg 
713.83 ± 270.28 ns 0.58 ± 0.09 ns 32.57 ± 8.46 ns 
CS5 (T) 325.73 ± 14.04 ns 0.45 ± 0.13 ns 26.40 ± 3.38 ns 
Values are presented as mean ± S.D. Statistical differences between formulations were calculated using 
Sidak´s multiple comparisons test (ns - not significant). 
  
Figure 3.1 - Physical characterization of CS3 (S) and CS5 (S) polyplexes. Statistical differences, 
compared to polyplexes without IGFBP peptides, were calculated using Dunnett´s multiple comparisons 
test (**p<0.01; * p<0.05 and ns - not significant). 
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No statistical differences were found between formulations, (S) and (T), with 
IGFBP-3 and IGFBP-5 peptides, respectively (Fig. 3.2). However, a slight increase on 
polyplex mean size was observed in (T) formulation when compared with (S) 
formulation. These results might indicate that when the total amount of IGFBP peptides 
is added to CS solution, polyplexes formation can be hampered due to a slight increase 
of polyplex aggregation accompanied by the increase of their mean size, leading to 
more heterogeneous preparations. Regarding zeta potential, similar results were 
observed between formulations (Fig. 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For formulations 15:1CS3 and 15:1CS5, we also choose a fixed peptide 
concentration of 100 µg and in order to evaluate differences of polyplex formation, 
these were prepared considering the total amount of amine groups, including peptides 
and polymer, at a IGFBP-3 or -5/CS:DNA (N:P ratio) of 15:1 and were characterized 
regarding their size, PdI and zeta potential, as depicted in Fig.3.3. 
Figure 3.2 - Comparison of physical characterization between CS3 (S) and CS3 (T), and CS5 (S) and CS5 
(T) polyplexes, with 100µg of IGFBP peptides, respectively. Statistical differences between polyplexes, 
with same kind of IGFBP peptides, were calculated using Sidak´s multiple comparisons test (ns - not 
significant). 
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This formulation yielded polyplexes with similar results in terms of mean size and 
zeta potential, when comparing both 15:1CS (T) and 15:1CS (S), with 100 µg of 
IGFBP-3 and IGFBP-5 peptides, respectively (Fig. 3.3). Regarding zeta potential, 
although there has been a reduction in amine groups available to interact with phosphate 
groups when IGFBP peptides were included in the ratio 15:1 (CS:DNA) and CS 
solution was adjusted, the surface charge of polyplexes was not affected yielding 
positively charged polyplexes (Fig. 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These results suggest that the reduction of amine groups did not significantly 
affect size and surface charge of polyplexes. According to the literature, N:P ratio is one 
of the factors which influence polyplexes size (Buschmann et al., 2013), in our study, a 
decrease in N:P ratio yielded polyplexes with similar sizes and surface charge to CS 
formulations. 
 
Figure 3.3 - Comparison of physical characterization of polyplexes 15:1CS, (S) and (T), with IGFBP-3 or 
IGFBP-5, respectively. Statistical differences between polyplexes, with same kind of IGFBP peptides, 
were calculated using Sidak´s multiple comparisons test (* p<0.05 and ns - not significant). 
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Several methods have been used to covalently bind NLS peptides to DNA, as 
described by Ciolina et al., 1999, which associated covalently NLS peptides to DNA by 
photoactivation, although plasmid-NLS conjugates have not been detected in the 
nucleus. Nagasaki et al., 2003, observed an increase on gene expression only when 5 
NLS peptides were covalently coupled to DNA by diazo coupling through a PEG chain 
and not when the NLS peptides were directly coupled to DNA. Zanta et al., 1999, 
obtained success on ligation of one NLS-oligonucleotide conjugated covalently to one 
or both ends of a linear DNA. However, extensive chemical modification of DNA 
causes reduction or inhibition of transfection process (Cartier et al., 2002; Nagasaki et 
al., 2003; Opanasopit et al., 2009; Yoo et al., 2007). 
In our study, to avoid chemical modification of DNA, NLS peptides were linked 
covalently to CS polymer (Fig. 2.6), and polyplexes were characterized regarding size, 
polydispersity and zeta potential, as shown in Table 3.3. 
 
 
Table 3.3 - Physical characterization of CSedac3 and CSedac5 polyplexes. 
Polyplex IGFBP (µg) Z-average size (nm) PdI Zeta potential (mV) 
CSedac3 
100 µg 
758.05 ± 159.88 ns 0.54 ± 0.16 ns 32.70 ± 12.02 ns 
CSedac5 689.20 ± 22.91 ns 0.39 ± 0.06 ns 41.20 ± 1.98 ns 
Values are presented as mean ± S.D. Statistical differences were calculated using Sidak´s multiple 
comparisons test (ns - not significant, compared to control CS). 
 
 
This formulation yielded polyplexes with an increased size, which might be due to 
the fact that IGFBP peptides with EDAC had been added to polyplexes previously 
prepared by method described on Fig. 2.3, corresponding to CS polyplexes (Fig. 3.1, 
100 µg IGFBP peptides). These results indicate that the addition of IGFBP peptides to 
CS formulation previously prepared result in similar sizes. Regarding the zeta potential, 
an increase of its mean values was expected, since IGFBP peptides were added to 
polyplexes previously prepared, resulting in the covalently bind of IGFBP peptides to 
the available amine groups of CS in the polyplex surface, giving it positive charge. 
 
Several studies have reported the potential use of the polymer HA in ternary 
complexes for gene delivery applications (De La Fuente et al., 2008 (a); de la Fuente et 
al., 2008 (b)), which can be incorporated into complexes without disrupting their 
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structures (Ito et al., 2006, 2010). In our study, this anionic polymer, HA, was 
incorporated into polyplexes preparations, and several concentrations of IGFBP 
peptides were added, namely, 10, 50 and 100 µg, as described above (Fig. 2.7). 
Polyplexes were characterized regarding their size, PdI and zeta potential, as shown in 
Table 3.4. 
 
 
Table 3.4 - Composition, size, PdI and zeta potential of CSHA3 and CSHA5 
polyplexes. 
Polyplex IGFBP (µg) Z-average size (nm) PdI Zeta potential (mV) 
CSHA 0 µg 375.20 0.62 37.80 
CSHA3 
10 µg 
353.60 ± 167.87 ns 0.64 ± 0.51 ns 37.35 ± 1.06 ns 
CSHA5 264.35 ± 55.65 ns 0.63 ± 0.53 ns 34.10 ± 3.96 ns 
CSHA3 
50 µg 
241.15 ± 18.03 ns 0.25 ± 0.04 ns 30.25 ± 2.62 * 
CSHA5 400.20 ± 75.80 ns 0.45 ± 0.02 ns 25.25 ± 2.47 * 
CSHA3 
100 µg 
281.85 ± 44.19 ns 0.26 ± 0.06 ns 29.95 ± 1.06 * 
CSHA5 556.80 ± 218.07 ns 0.55 ± 0.14 ns 18.85 ± 4.03 ** 
Values are presented as mean ± S.D. Statistical differences were calculated using Dunnett’s multiple 
comparisons test (**p<0.01; * p<0.05 and ns - not significant, compared to control CSHA (nanoparticles 
without IGFBP peptides)). 
 
 
According to the literature, addition of HA causes variations in size and zeta 
potential of polyplexes (De La Fuente et al., 2008), namely an increase in size and a 
decrease in surface charge (Ito et al., 2006, 2010). This was not observed in our study, 
since polyplexes without IGFBP peptides, CSHA, yielded polyplexes with a decrease in 
size and an increase in potential zeta when compared with CS polyplexes, without 
IGFBP peptides and HA. These results might suggest that when HA was added to CS 
solution, which might have affected the entanglement of CS chains, it was mostly 
entrapped inside the polyplexes, and thus not contributing to a decrease of the zeta 
potential. 
Regarding polyplexes prepared with several concentrations of IGFBP peptides, no 
statistical differences were found on mean size of polyplexes when compared with 
CSHA polyplexes, yielding polyplexes with mean size between 250-550 nm. However, 
statistical differences were found in the zeta potential, which was dependent of 
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concentration of IGFBP peptides, when compared with CSHA polyplexes. These results 
indicate that addition of IGFBP peptides on polyplexes preparation influenced their size 
and zeta potential, and mainly the decrease of zeta potential was concentration-
dependent of IGFBP peptides. 
 
The efficiency of cellular uptake, as well as endocytic pathway of particle entry 
and intracellular tracking are factors size-dependents of polyplexes. According to 
literature, large particles present less internalization than small particles but, however, 
have a higher rate of gene release into the cytosol due to the prolonged residence time in 
cytosol of large particles. This prolonged residence time indicates that large particles 
may avoid rapid lysosomal degradation. Particles with size >200 nm up to >1 µm are 
internalized mainly by caveolae-mediated endocytosis (Rejman et al., 2004), wherein 
the motility of caveolae is relatively low but depends on the actin filaments and 
microtubules network (Le Roy & Wrana, 2005). Taking into account that all 
formulations in our study yielded polyplexes with a distribution of very heterogeneous 
size, with ranges between 250 nm up to 750 nm, these results suggest that the 
predominant polyplexes internalization pathway may be caveolae-mediated endocytosis. 
The surface charge also affects the cellular uptake level of the polyplexes, and 
according to the literature positively charged polyplexes interact efficiently with the cell 
membrane (Agirre et al., 2014). All formulations in our study yielded polyplexes 
positively charged favoring the internalization. 
These results suggest appropriated characteristics of polyplexes, either size as 
surface charge, which indicate that may be applied as gene delivery systems. 
 
 
3.2 Evaluation of DNA complexation 
 
The DNA complexation by all polyplexes formulations described above was 
evaluated by agarose gel electrophoresis. DNA complexation was achieved for all 
formulations which was observed by the absence of free DNA migration into the gel 
(Fig. 3.4). These results indicate that all polyplexes complexed DNA effectively 
regardless of the IGFBP concentration tested. 
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3.3 Evaluation of cell viability 
 
The cytotoxicity of IGFBP peptides on HEK293T cells was measured through a 
MTT assay, at 24h and 72h, with increasing amounts of IGFBP-3 or IGFBP-5 peptides, 
as depicted in Fig. 3.5. No cytotoxicity was observed for either IGFBP peptides 
regardless of the tested concentration, since cell viability (%) was above 70% for all 
tested concentrations. These results suggest that the IGFBP peptides are not cytotoxic to 
cells and may even show some proliferative effect shown by the high values of cell 
viability at 24h, followed of a decrease at 72h. According to the literature, IGFBP-3 has 
been described as having the potential to modulate apoptosis (Baxter, 2001), while 
IGFBP-5 has an important role in controlling cell survival, differentiation and apoptosis 
(Baxter, 2001; Beattie et al., 2006), which may explain these results. However, it would 
be interesting to test other peptides concentrations but due to time constrictions and lack 
of available biological material it was not possible to do so. 
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Figure 3.4 – Representative images of evaluation of DNA complexation by polyplexes by agarose gel 
electrophoresis. Polyplexes showed an efficient DNA complexation, visualized by GreenSafe Premium 
(data shown for some formulations). M - DNA marker 
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Figure 3.5 - Cell viability (%) after 24h and 72h of incubation with several IGFBP peptides 
concentrations, respectively. Cells untreated were used as positive control and cells incubated with latex 
extracts as negative control. Statistical differences, compared to positive control, were calculated using 
Dunnett’s multiple comparisons test (**** p<0.0001;*** p<0.001, ** p<0.01 and ns - not significant). 
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3.4 Transfection efficiency evaluation 
 
To evaluate transfection efficiency of formulations characterized above a series of 
transfection assays were performed in HEK293T cells. Gene transfection was evaluated 
through GFP expression, which was visualized by fluorescence microscopy after 48h 
and 72h, and lastly, transfection efficiency was analyzed by flow cytometry at 72h. 
To evaluate transfection efficiency of CSNa2SO4 polyplexes, a range of 
concentrations between 10 µg and 150 µg of IGFBP-3 peptides, corresponding to 
CSNa2SO43, were co-administrated at the time of transfection as described above. 
Polyplexes associated with IGFBP-5, corresponding to CSNa2SO45, were co-
administered with only the three lower concentrations, since no improvement was 
observed with higher concentrations of peptides (Fig. 3.8) and due to limited amount of 
available biological material. Polyplexes were visualized by fluorescence microscopy at 
48h and 72h, as shown in Fig. 3.6 and Fig. 3.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.6 - Representative images of fluorescence microscopy of transfected cells by CSNa2SO43 
polyplexes with several concentrations of IGFBP-3, after 48h and 72h, left and right panel, respectively.  
Amplification of 100X and scale bar represents 1µm. 
Bright field Fluorescence Bright field Fluorescence 
25 µg 
50 µg 
100 µg 
150 µg 
10 µg 
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The in vitro transfection ability of CS/DNA complexes, without IGFBP peptides, 
was evaluated in HEK293T cells and displayed in Fig. 3.8. The results of flow 
cytometry analysis, that detect GFP expression, indicated a relatively low transfection 
efficiency of polyplexes without IGFBP peptides when compared with cells transfected 
with FuGENE®, a commercial transfection reagent, which was used as positive control. 
Similar results were achieved in a study, with the same preparation method of 
polyplexes in HEK293 cells, where a low transfection efficiency of CS/DNA complexes 
was obtained when compared with Lipofectamine™, a transfection reagent (Mao et al., 
2001). 
Regarding to polyplexes co-administrated with several concentrations of IGFBP 
peptides, contrary to our expectations, no transfection efficiency increase was observed 
for either peptide regardless of the tested concentrations, when compared with 
polyplexes without IGFBP peptides (Fig. 3.8). Moreover, polyplexes with IGFBP-5 
peptides registered a significant decrease in transfection when compared with 
polyplexes without IGFBP peptides. These results indicate that despite polyplexes 
presenting an appropriate size for gene delivery, lower than 500 nm, and positive 
surface charge, the co-administration of increasing amounts of IGFBP peptides did not 
improve transfection efficiency of polyplexes. Although NLS cationic peptides, 
Figure 3.7 - Representative images of fluorescence microscopy of transfected cells by CSNa2SO45 
polyplexes with several concentrations of IGFBP-5 peptides, after 48h and 72h, left and right panel, 
respectively. Amplification of 100X and scale bar represents 1 µm.. 
10 µg 
25 µg 
50 µg 
Bright field Fluorescence Bright field Fluorescence 
3. Results and Discussion 
45 
containing lysine and arginine, are capable of binding nonspecifically to DNA by 
electrostatic interactions (Bremner et al., 2004), in our study, when IGFBP peptides are 
co-administrated with polyplexes, the interaction between IGFBP peptides and DNA 
might have been hampered, and thus nuclear entry of DNA appears to be similar with 
and without IGFBP peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As described above, to evaluate if sodium sulfate influences polyplexes formation, 
this was omitted, and CS3 and CS5 polyplexes were prepared with increasing 
concentrations of IGFBP-3 and IGFBP-5 peptides, respectively, which were co-
complexed at the time of polyplexes preparation. GFP expression was evaluated by 
fluorescence microscopy, as shown in Fig. 3.9 and Fig. 3.10. 
 
  
Figure 3.8 - Transfection efficiency represented by percentage of GFP positive cells. Statistical 
differences were calculated using Dunnett´s multiple comparisons test compared with polyplexes without 
IGFBP peptides (**** p<0.0001; ** p<0.01 and ns - not significant). Transfection was performed at a 
dose of 1µg of DNA for all groups and analyzed 72h after transfection. 
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Figure 3.9 - Representative images of fluorescence microscopy of transfected cells by CS3 (S) polyplexes 
with several concentrations of IGFBP-3, after 48h and 72h, left and right panel respectively.  
Amplification of 100X and scale bar represents 1µm. 
10 µg 
50 µg 
100 µg 
 
Bright field Fluorescence Bright field Fluorescence 
250 µg 
Figure 3.10 - Representative images of fluorescence microscopy of transfected cells by CS5 (S) 
polyplexes with several concentrations of IGFBP-5, after 48h and 72h, left and right panel respectively. 
Amplification of 100X and scale bar represents 1µm. 
10 µg 
50 µg 
100 µg 
 
Bright field Fluorescence Bright field Fluorescence 
250 µg 
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NLSs can be coupled to DNA or to vectors, to improve gene delivery, however, 
it is not yet clear what is the best form to incorporate the NLS peptides to gene delivery 
systems (Hébert, 2003). Several studies have widely investigated ways to incorporate 
NLS peptides, either covalently or non-covalently, to gene delivery systems. Yoo et al., 
2007, attached psoralen-NLS conjugates non-covalently to DNA/PEI complexes, and an 
increase in transfection efficiency in COS-1 cells was observed, when compared with a 
mutant NLS or DNA/PEI complexes without NLS peptides. Opanasopit et al., 2009, 
incorporated directly, without covalent conjugation, NLS peptides to DNA or CS 
polymer. The CS/DNA complexes, with increasing amounts of NLS peptides co-
complexed, increased transfection efficiency into Hela cells, in a NLS-dose dependent 
manner, in comparison to CS/DNA complexes without NLS peptides. 
In our study, we prepared CS3 and CS5 polyplexes with increasing 
concentrations of IGFBP-3 and IGFBP-5 peptides co-complexed, respectively, and 
analyze GFP expression by flow cytometry at 72h. As shown in Fig. 3.11, a significant 
increase in transfection efficiency was observed with polyplexes co-complexed with 
IGFBP-3 peptides, when compared to polyplexes without IGFBP peptides. However, 
regarding to polyplexes co-complexed with IGFBP-5 peptides, contrary to our 
expectations, no significant transfection efficiency increase was observed when 
compared with polyplexes without IGFBP peptides. 
These results indicate that IGFBP-3 peptides improve transfection efficiency of 
polyplexes, however, similar results were not observed with CS5 polyplexes. Previous 
studies reported that the affinities or accessibility to importin subunits differ between 
IGFBP-3 and IGFBP-5, although they are not clear (Schedlich et al., 2000), which could 
explain the difference of results observed in Fig. 3.11. When IGFBP-5 peptides are co-
complexed with CS polyplexes, the accessibility of peptides to their nuclear receptors, 
importins, might be hampered and hence the DNA nuclear delivery is lower, not 
contributing to an improvement of transfection efficiency. 
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To evaluate if the mixing technique influences the performance of polyplexes, a 
fixed concentration of 100 µg was chosen based on results in Fig. 3.11, showing an 
increase in transfection efficiency of polyplexes, and polyplexes were prepared as 
described above. Transfection assays were performed in HEK293T cells and visualized 
by fluorescence of microscopy at 48h and 72h, as displayed in Fig. 3.12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CS5 (T) 
CS3 (T) 
Figure 3.12 - Representative images of fluorescence microscopy of transfected cells by CS3 and CS5, (T), 
polyplexes with 100 µg of IGFBP-3 or IGFBP-5, respectively. Cells were visualized after 48h and 72h, 
left and right panel, respectively. Amplification of 100X and scale bar represents 1µm. 
Bright field Fluorescence Bright field Fluorescence 
Figure 3.11 - Transfection efficiency represented by percentage of GFP positive cells, of CS3 (S) and 
CS5(S) polyplexes. Statistical differences were calculated using Dunnett´s multiple comparisons test 
compared with polyplexes without IGFBP peptides (**** p<0.0001; * p<0.05 and ns - not significant). 
Transfection was performed at a dose of 1µg of DNA for all groups and analyzed 72h after transfection. 
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Figure 3.13 - Transfection efficiency represented by percentage of GFP positive cells of CS3 (S) and (T) 
and CS5 (S) and (T) polyplexes, both with 100µg of IGFBP peptides, respectively. Statistical differences 
compared with polyplexes without IGFBP peptides were calculated using Dunnett´s multiple 
comparisons test (**** p<0.0001; * p<0.05 and ns - not significant). Transfection was performed at a 
dose of 1µg of DNA for all groups and analyzed 72h after transfection. 
Transfection assays of CS3 (T) and CS5 (T) polyplexes were analyzed after 72h 
by flow cytometry and compared with transfection assays performed with CS3 (S) and 
CS5 (S) with 100 µg of IGFBP peptides, respectively, and displayed in Fig. 3.13. 
According to the obtained results in Fig. 3.11, a significant increase in transfection 
efficiency of polyplexes with IGFBP-3 peptides was observed, while polyplexes with 
IGFBP-5 peptides obtained similar results to polyplexes without IGFBP peptides (Fig. 
3.13). These results indicate that according to previous results (Fig. 3.11), IGFBP-3 
peptides improve, in fact, transfection efficiency of polyplexes when compared with 
polyplexes without IGFBP peptides, and although, the mixing technique used affect the 
size of polyplexes (Fig. 3.2), it does not appear to affect their effectiveness, as 
previously reported (Buschmann et al., 2013). Regarding CS5 (T) polyplexes, these 
similar results to previous results with CS5 (S) polyplexes suggest once again that, 
when IGFBP-5 is co-complexed in polyplexes, the recognition of peptides by import 
proteins might be hampered and hence not contributing to an improve of transfection 
efficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For formulations 15:1CS3 and 15:1CS5, (S) and (T), we also choose a 
concentration of 100 µg in order to evaluate the differences between formulations, and 
polyplexes were prepared as described above. Fluorescence microscopy was used to 
visualize the transfection assays after 48h and 72h, as shown in Fig. 3.14 and Fig. 3.15. 
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Transfection efficiencies were analyzed through GFP expression by flow 
cytometry, after 72h, and shown in Fig. 3.16. For these formulations, 15:1CS3 and 
15:1CS5, we also choose a fixed peptide concentration of 100 µg in order to evaluate 
differences between polyplexes formulations, and these were prepared considering the 
total amount of amine groups, including peptides and polymer, at a IGFBP-3 or -
5/CS:DNA (N:P ratio) of 15:1. Although amine groups have been reduced, since the 
amount of CS was adjusted and peptides were included in the N:P ratio, a significant 2-
fold increase in transfection efficiency was observed to 15:1CS3 polyplexes, (S) and 
(T), when compared with polyplexes without IGFBP peptides, corresponding to NP 
complexes (Fig. 3.16). According to previous results, shown in Fig. 3.8 and Fig. 3.11, 
Figure 3.14 - Representative images of fluorescence microscopy of transfected cells by 15:1CS3 (S) and  
15:1CS3 (T) polyplexes with 100 µg of IGFBP-3, after 48h and 72h, left and right panel, respectively. 
Amplification of 100X and scale bar represents 1 µm. 
15:1CS3 
(T) 
15:1CS3 
(S) 
Bright field Fluorescence Bright field Fluorescence 
Figure 3.15 - Representative images of fluorescence microscopy of transfected cells by 15:1CS5 (S) and  
15:1CS5 (T) polyplexes with 100 µg of IGFBP-5, after 48h and 72h, left and right panel, respectively. 
Amplification of 100X and scale bar represents 1 µm. 
15:1CS5 
(T) 
15:1CS5 
(S) 
Bright field Fluorescence Bright field Fluorescence 
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no transfection efficiency increase was observed in polyplexes with IGFBP-5 peptides 
when compared to NP complexes (Fig. 3.16). 
The N:P ratio has been widely investigated (Boulanger et al., 2005; Bremner et al., 
2004; Buschmann et al., 2013; Mao et al., 2001; Opanasopit et al., 2009) and described 
as one of the factors which influence polyplexes formation (size and surface charge), 
although in our study this influence have not been observed, as well as transfection 
efficiency (Agirre et al., 2014). 
However, taking into account our results (Fig. 3.16), although N:P ratio has been 
slightly changed in this formulation, it did not influence transfection efficiency of 
polyplexes. Polyplexes co-complexed with IGFBP-3 peptides yielded a significant 
increase in transfection efficiency and polyplexes co-complexed with IGFBP-5 peptides 
not improved of transfection efficiency, when compared to NP complexes, as expected 
by previous results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several methods for covalent attachment of molecules to DNA have been 
developed and reported (Ciolina et al., 1999; Nagasaki et al., 2003; Neves, Byk, 
Scherman, & Wils, 1999; Zanta et al., 1999). However, the chemical modification of 
DNA might cause a decrease in their gene expression (Cartier et al., 2002; Yoo et al., 
2007). In our study, we linked IGFBP peptides covalently to CS polymer by amide 
Figure 3.16 - Transfection efficiency represented by percentage of GFP positive cells of 15:1CS3 (S) and 
(T) and 15:1CS5 (S) and (T) polyplexes, both with 100 µg of IGFBP peptides, respectively. Statistical 
differences compared with NP were calculated using Dunnett´s multiple comparisons test (**** 
p<0.0001; *** p<0.001 and ns - not significant). Transfection was performed at a dose of 1µg of DNA for 
all groups and analyzed 72h after transfection. 
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bond formation between the carboxylic acid moieties of the IGFBP peptides and the 
amine groups of CS, which was mediated by a carbodiimidine (EDAC). Transfection 
assays were visualized at 48h and 72h by fluorescence microscopy, as depicted in Fig. 
3.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Fig. 3.18, analysis of transfection efficiency at 72h by flow 
cytometry revealed a 2-fold enhancement in transfection efficiency with CSedac3 
polyplexes, when compared to NP complexes, without IGFBP peptides. While no 
transfection efficiency increase was observed for CSedac5 polyplexes comparatively to 
NP complexes. Contrary to our expectations, CSedac3 and CSedac5 polyplexes yielded 
similar transfection efficiencies to previously described formulations. These results 
indicate that transfection efficiency is improved by polyplexes with IGFBP-3 peptides 
but not with polyplexes with IGFBP-5 peptides, suggesting, as previously described, 
that recognition of IGFBP-5 peptides by importins may be being hampered by their 
entanglement in polyplexes preparation. 
 
  
Figure 3.17 - Representative images of fluorescence microscopy of transfected cells by CSedac3 and   
CSedac5 polyplexes with 100 µg of IGFBP-3 or -5, respectively. Cells were visualized after 48h and 72h, 
left and right panel, respectively. Amplification of 100X and scale bar represents 1 µm. 
CSedac5 
CSedac3 
Bright field Fluorescence Bright field Fluorescence 
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Figure 3.18 - Transfection efficiency represented by percentage of GFP positive cells of CSedac3 and 
CSedac5 polyplexes, both with 100µg of IGFBP peptides, respectively. Statistical differences compared 
with NP were calculated using Dunnett´s multiple comparisons test (**** p<0.0001; ** p<0.01 and ns - 
not significant). Transfection was performed at a dose of 1µg of DNA for all groups and analyzed 72h 
after transfection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The final goal of a gene delivery system is to produce a significant level of 
transfection efficiency, however, we should take into account, factors as N:P ratio, MW, 
pH of transfection medium, plasmid concentration, among others, since these factors 
can influence transfection efficiency of gene delivery systems (Contreras-Ruiz et al., 
2011; Lu et al., 2011). The transfection efficiency of CS complexes has been widely 
investigated and can be improved by combining CS with anionic biopolymers, as HA 
(Lu et al., 2011). Taking this approach into account, in our study, polyplexes with HA 
were prepared and a ratio 5:1 (CS:HA) was chosen according to Lu et al., 2011, since 
transfection efficiencies of CS/HA polyplexes were investigated using ratios from 1 to 
5, being the highest level reached at an N:P ratio of 5:1 (CS:HA). Polyplexes were 
prepared with increasing amounts of IGFBP-3 and IGFBP-5 peptides, respectively, and 
transfection efficiency was visualized at 48h and 72h by fluorescence microscopy, as 
shown in Fig. 3.19 and 3.20. 
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Figure 3.19 - Representative images of fluorescence microscopy of transfected cells by CSHA3 
polyplexes with several concentrations of IGFBP-3 peptides, after 48h and 72h, left and right panel, 
respectively. Amplification of 100X and scale bar represents 1 µm. 
10 µg 
50 µg 
100 µg 
 
Bright field Fluorescence Bright field Fluorescence 
Figure 3.20 - Representative images of fluorescence microscopy of transfected cells by CSHA5 
polyplexes with several concentrations of IGFBP-5, after 48h and 72h, left and right panel, respectively. 
Amplification of 100X and scale bar represents 1 µm. 
10 µg 
50 µg 
100 µg 
 
Bright field Fluorescence Bright field Fluorescence 
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Figure 3.21 - Transfection efficiency represented by percentage of GFP positive cells of CSHA3 and 
CSHA5 polyplexes. Statistical differences, compared with polyplexes without IGFBP peptides, were 
calculated using Dunnett´s multiple comparisons test (**** p<0.0001; ** p<0.01, * p<0.05 and ns - not 
significant). Transfection was performed at a dose of 1µg of DNA for all groups and analyzed 72h after 
transfection. 
Transfection efficiencies were analyzed at 72h by flow cytometry, as shown in 
Fig. 3.21. For these formulations, HA was incorporated into polyplexes preparation, and 
according to literature (Ito et al., 2010; Lu et al., 2011), an increase in transfection 
efficiency of polyplexes CS/HA, without IGFBP peptides, was expected, when 
compared with previously obtained results with CS complexes. 
Regarding to polyplexes co-complexed with IGFBP-3 peptides, a significant 2-
fold increase in transfection efficiency was observed when compared to polyplexes 
without IGFBP peptides. Moreover, a significant increase in transfection efficiency was 
also observed in polyplexes co-complexed with IGFBP-5 peptides, when compared to 
polyplexes without IGFBP peptides. The transfection efficiency increased when the 
amount of IGFBP-5 peptides increased and reached the maximum at 50 µg, followed by 
a decrease by further increments of IGFBP-5 peptides, suggesting that addition of HA 
may modify the entanglement of CS chains favoring the IGFBP-5 peptides recognition 
by importins, and thus, improve DNA nuclear delivery in a concentration dependent 
manner. 
The results indicate that addition of HA to polyplexes improves transfection 
efficiency of polyplexes, as previously reported (Lu et al., 2011), when compared to CS 
polyplexes. Furthermore, these results indicate that polyplexes co-complexed with 
increasing amounts of IGFBP peptides, respectively, are significantly more efficient in 
mediating transfection, depending of concentration of IGFBP peptides, than the CS/HA 
polyplexes. 
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This study had as goal to characterize and optimize CS-based non-viral gene 
delivery systems, improving the transfection efficiency of polyplexes by incorporation 
of IGFBP peptides, using HEK293T cell line to evaluate their effectiveness. 
In this work, we approached three strategies of incorporation of IGFBP peptides 
in polyplexes, co-administration at the time of transfection, co-complexation and 
covalent ligation to CS polymer. Firstly, we started by characterizing the physical 
properties of polyplexes, as their size, PdI and zeta potential, since these are factors that 
can influence the cellular uptake efficiency, and hence, condition all the transfection 
process. 
Taking our results into account, we observed, by the addition and removal of 
sodium sulfate from polyplexes, that this has a role in polymer entanglement, since its 
addition yielded polyplexes with lower size and surface charge. We also observed that 
addition of increased amounts of IGFBP peptides to polyplexes, influenced physical 
properties of polyplexes, as their size and surface charge, which were concentration-
dependent of IGFBP peptides. However, regardless of the mixing technique, presence 
of sodium sulfate, N:P ratio, addition of IGFBP peptides, or even, incorporation of a 
second polymer, HA, all polyplexes formulations yielded polyplexes positively charged, 
capable of an effective DNA complexation, with an appropriate size (> 1 µm) to their 
use in gene delivery applications. The IGFBP peptides were also submitted to cellular 
viability assays, which revealed that peptides are not cytotoxic to HEK293T cells, 
however, it would be interesting to test other peptide concentrations. 
Lastly, in vitro transfection assays were performed to evaluate transfection 
efficiency of polyplexes, which showed that transfection efficiency of polyplexes was 
concentration-dependent of IGFBP peptides as well as of gene delivery systems 
employed. 
In transfection studies with polyplexes co-administrated with increased amounts 
of IGFBP peptides, no transfection efficiency increase was observed. When IGFBP 
peptides are co-administrated with polyplexes, these can be rapidly degraded in the 
extracellular environment and cellular intake may not be achieved. On the other hand, 
formulations of polyplexes without HA, co-complexed with increasing amounts of 
IGFBP peptides, revealed a 2-fold increase in transfection efficiency to IGFBP-3 
peptides. A possible explanation for these results may be related to differing affinities or 
accessibilities to importin subunits between IGFBP-3 and IGFBP-5 peptides, although 
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not clear. The approach of IGFBP peptides incorporation covalently bind to CS, 
revealed similar results to polyplexes without HA co-complexed with IGFBP peptides. 
Lastly, a second polymer was incorporated into polyplexes formulation, HA 
polymer. These results showed an increase in transfection efficiency to both IGFBP 
peptides co-complexed with polyplexes, which may be explained by the addition of HA 
into polyplexes, suggesting a modification in CS chains entanglement favoring 
increased IGFBP-5 peptides recognition by importins, and thus, improved of DNA 
nuclear delivery. 
To the best of our knowledge, this is the first study where IGFBP peptides are 
associated to CS-based non-viral gene carriers used for gene delivery. On the whole, the 
results shown that, although optimization of transfection efficiency is still needed, 
polyplexes co-complexed with IGFBP peptides are indeed good candidates for non-viral 
gene delivery systems. The polyplexes with two combined polymers, chitosan and 
hyaluronic acid, were those that showed greater transfection efficiencies for both 
peptides, IGFBP-3 and IGFBP-5, being considered the best formulation in our study. 
In the future, it would be interesting not only expanding the range of 
concentrations tested IGFBP peptides as well as the type of cell lines, further 
comprising the optimization of the formulations of polyplexes. 
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